“Cataract – Pipeline Review, H1 2015
Summary
Global Markets Direct’s, ‘Cataract – Pipeline Review, H1 2015’, provides an overview of the Cataract’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Cataract, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cataract and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
– The report provides a snapshot of the global therapeutic landscape of Cataract
– The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in the therapeutics development for Cataract and enlists all their major and minor projects
– The report summarizes all the dormant and discontinued pipeline projects
– A review of the Cataract products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– A detailed assessment of monotherapy and combination therapy pipeline projects
– Coverage of the Cataract pipeline on the basis of target, MoA, route of administration and molecule type
– Latest news and deals relating related to pipeline products
Reasons to buy
– Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Develop strategic initiatives by understanding the focus areas of leading companies
– Identify and understand important and diverse types of therapeutics under development for Cataract
– Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
– Devise corrective measures for pipeline projects by understanding Cataract pipeline depth and focus of Indication therapeutics
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline”
“Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Cataract Overview 7
Therapeutics Development 8
Pipeline Products for Cataract – Overview 8
Pipeline Products for Cataract – Comparative Analysis 9
Cataract – Therapeutics under Development by Companies 10
Cataract – Therapeutics under Investigation by Universities/Institutes 11
Cataract – Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Cataract – Products under Development by Companies 14
Cataract – Products under Investigation by Universities/Institutes 15
Cataract – Companies Involved in Therapeutics Development 16
CalAsia Pharmaceuticals, Inc. 16
EyeGate Pharmaceuticals, Inc. 17
InSite Vision Incorporated 18
Laboratorios Sophia S.A. de C.V. 19
Laila Pharmaceuticals Pvt. Ltd. 20
Omeros Corporation 21
R-Tech Ueno, Ltd. 22
Cataract – Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Combination Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 32
(bromfenac sodium + dexamethasone acetate) – Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
(sulfasalazine + Hyaluronic Acid) – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
dexamethasone acetate – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
LP-01309 – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
PRO-155 – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
RTU-007 – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecule to Antagonize GPR161 for Metastatic Epithelial Cancers, Congenital Cataracts and Birth Defects of the Brain and Spinal Cord – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Small Molecule to Inhibit NFkB for Ophthalmology, Oncology and Immunology – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Small Molecules for Non-Surgical Cataracts and Multiple Sclerosis – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Small Molecules for Ophthalmology and CNS Disorders – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Small Molecules for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Cataract – Recent Pipeline Updates 45
Cataract – Dormant Projects 47
Cataract – Discontinued Products 48
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 49
Disclaimer 50″
“List of Tables
Number of Products under Development for Cataract, H1 2015 8
Number of Products under Development for Cataract – Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Products under Investigation by Universities/Institutes, H1 2015 15
Cataract – Pipeline by CalAsia Pharmaceuticals, Inc., H1 2015 16
Cataract – Pipeline by EyeGate Pharmaceuticals, Inc., H1 2015 17
Cataract – Pipeline by InSite Vision Incorporated, H1 2015 18
Cataract – Pipeline by Laboratorios Sophia S.A. de C.V., H1 2015 19
Cataract – Pipeline by Laila Pharmaceuticals Pvt. Ltd., H1 2015 20
Cataract – Pipeline by Omeros Corporation, H1 2015 21
Cataract – Pipeline by R-Tech Ueno, Ltd., H1 2015 22
Assessment by Monotherapy Products, H1 2015 23
Assessment by Combination Products, H1 2015 24
Number of Products by Stage and Target, H1 2015 26
Number of Products by Stage and Mechanism of Action, H1 2015 28
Number of Products by Stage and Route of Administration, H1 2015 30
Number of Products by Stage and Molecule Type, H1 2015 31
Cataract Therapeutics – Recent Pipeline Updates, H1 2015 45
Cataract – Dormant Projects, H1 2015 47
Cataract – Discontinued Products, H1 2015 48″
“List of Figures
Number of Products under Development for Cataract, H1 2015 8
Number of Products under Development for Cataract – Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Comparative Analysis by Early Stage Products, H1 2015 13
Assessment by Monotherapy Products, H1 2015 23
Number of Products by Top 10 Targets, H1 2015 25
Number of Products by Stage and Top 10 Targets, H1 2015 26
Number of Products by Top 10 Mechanism of Actions, H1 2015 27
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 28
Number of Products by Top 10 Routes of Administration, H1 2015 29
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 30
Number of Products by Stage and Top 10 Molecule Types, H1 2015 31″
“CalAsia Pharmaceuticals, Inc.
EyeGate Pharmaceuticals, Inc.
InSite Vision Incorporated
Laboratorios Sophia S.A. de C.V.
Laila Pharmaceuticals Pvt. Ltd.
Omeros Corporation
R-Tech Ueno, Ltd.”
